Role of the progesterone receptor (PR) and the PR isoforms in breast cancer

Critical Reviews in Oncogenesis

Volumn 13, Issue 4, 2007, Pages 283-301

  Mc Cormack, Orla ^a   Harrison, Michèle ^b   Kerin, Michael J ^a,c   McCann, Amanda ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Breast cancer; GAS6; Hormone therapy; Progesterone receptor (PR)

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; FOLLITROPIN; FULVESTRANT; GONADORELIN; GOSERELIN; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RISK; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE MARKER; DRUG MECHANISM; DRUG RESPONSE; EXON; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MENOPAUSE; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 43249102252     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevoncog.v13.i4.20     Document Type: Review

References (74)